ReviewCancers2021
The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives-State of the Art.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Robotic-assisted versus video-assisted thoracoscopic anatomical lung resection for early-stage non-small cell lung cancer: a systematic review and meta-analysis.Journal of robotic surgery · 2026Pooled it
- Evaluating Surgical Approaches in Early NSCLC: A Meta-Analysis of Robot-Assisted and Video-Assisted Techniques.Annals of surgical oncology · 2026Pooled it
- Prehabilitation: preoperative rehabilitation interventions for lung cancer - a scoping review.Frontiers in aging · 2025Pooled it
- Effect of Exercise and Pulmonary Rehabilitation in Pre- and Post-Surgical Patients with Lung Cancer: Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Bronchoscopic Ablation and Intratumoral Therapies for Lung Cancer: Expanding Local Treatment Beyond Surgical Resection.Cancers · 2026Review
- mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.Journal, genetic engineering & biotechnology · 2026Review
- Is sublobar resection equivalent to lobectomy in Black and Hispanic patients with clinical stage IA non-small cell lung cancer?JTCVS open · 2026Article
- Recent advances in engineered nanozymes for precision lung cancer therapy.Materials today. Bio · 2026Review
- Article
- Suction Impact on Chest Drain Duration After Lung Resection: A Study Using Digital Drainage Systems.Journal of clinical medicine · 2026Article
- Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Textbook outcome and long-term survival after pulmonary resection for non-small cell lung cancer: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Article
- Global awareness and integration of immunotherapy among thoracic surgeons: a multicenter survey study.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Article
- Factors Associated With Readmission to Index vs. Non-Index Hospitals After Major Cancer Surgery.Cancer medicine · 2025Article
- Predictors of Postoperative Pneumonia Following Anatomical Lung Resections in Thoracic Surgery.Journal of clinical medicine · 2025Article
- Digital Versus Conventional Chest Drainage Systems in Resource-limited Setting: A Comparative Analysis.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study.Journal of immunotherapy and precision oncology · 2025Article
- Long noncoding RNA TMPO-AS1 upregulates chromosomal passenger complex expression to promote cell proliferation in lung cancer via sponging microRNA let-7b-5p.Cell division · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancers (NSCLC) are different today, due to the increased use of screening programs and of innovative systemic therapies, leading to the diagnosis of earlier and pre-invasive tumors, and of more advanced and controlled metastatic tumors. Surgery for NSCLC remains the cornerstone treatment when it can be performed. The role of surgery and surgeons has also evolved because surgeons not only perform the initial curative lung cancer resection but they also accompany and follow-up patients from pre-operative rehabilitation, to treatment for recurrences. Surgery is personalized, according to cancer characteristics, including cancer extensions, from pre-invasive and local tumors to locally advanced, metastatic disease, or residual disease after medical treatment, anticipating recurrences, and patients' characteristics. Surgical management is constantly evolving to offer the best oncologic resection adapted to each NSCLC stage. Today, NSCLC can be considered as a chronic disease and surgery is a valuable tool for the diagnosis and treatment of recurrences, and in palliative conditions to relieve dyspnea and improve patients' comfort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.